Denali Therapeutics, Inc. (DNLI)
20.22
+0.84
(+4.31%)
USD |
NASDAQ |
May 27, 16:00
20.23
+0.02
(+0.07%)
After-Hours: 18:40
Denali Therapeutics Free Cash Flow : -419.23M for March 31, 2026
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Biogen, Inc. | 2.316B |
| Neurocrine Biosciences, Inc. | 831.30M |
| Arcturus Therapeutics Holdings, Inc. | -63.18M |
| Agenus, Inc. | -87.53M |
| Curis, Inc. | -28.95M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -131.20M |
| Cash from Investing (Quarterly) | 94.46M |
| Cash from Financing (Quarterly) | 219.04M |
| Free Cash Flow Per Share (Quarterly) | -0.7162 |
| Free Cash Flow to Equity (Quarterly) | -131.43M |
| Free Cash Flow to Firm (Quarterly) | -133.67M |
| Free Cash Flow Yield | -11.75% |